~~<i id='6C6632E7B5'><strike id='6C6632E7B5'><tt id='6C6632E7B5'><pre id='6C6632E7B5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

comprehensive

author：entertainment 2025-09-30 22:05:52 - browse：41

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： FDA struggles to regulate food additives, sometimes for decades

knowledge

leisure time

Wikipedia

knowledge

focus

Wikipedia

WhichpresentationsareworthcatchingatASCOthisweekend?Whatisexon-skipping?Andhowdoyoupronouncebronchie

WSS

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

STAT Summit: How a Chicago ER doctor tackles gun violence

Pharmacists can make shortage drugs, but at what cost?

FDA gives detailed accounting of AI

How to increase colonoscopy rates? Looks like an AI can help

Impact of Dobbs ruling felt at reproductive medicine meeting

entertainment

comprehensive

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Intellia reports positive results for its CRISPR

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ionis drug prevents swelling attacks due to hereditary angioedema

Anesthesiologist group: stop taking Ozempic before surgery

Studies point to risks of excluding people with obesity from drug trials

BioMarin wins approval for gene therapy to treat hemophilia A

FDA warns J&J's Abiomed: We will regulate your software

New air purifier tech could be key to improving indoor air quality

Senate committee scrutinizes Medicare Advantage brokers

leisure time

Ultragenyx gene therapy for rare liver ailment succeeds in late

The explosion of genetic testing requires a new approach

ASCO: AstraZeneca says CAR

Intellia reports positive results for its CRISPR

Letters to First Opinion on caregivers, digital health, and more

Medicare reduced heart disease by changing how it pays doctors

Wikipedia

knowledge

focus

Wikipedia